BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

537 related articles for article (PubMed ID: 17484919)

  • 1. Management of clinical stage I nonseminomatous germ cell testicular cancer.
    Choueiri TK; Stephenson AJ; Gilligan T; Klein EA
    Urol Clin North Am; 2007 May; 34(2):137-48; abstract viii. PubMed ID: 17484919
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nonseminomatous germ cell testicular tumors clinical stage I: differentiated therapeutic approach in comparison with therapeutic approach using surveillance strategy only.
    Ondrus D; Ondrusova M; Hornak M; Matoska J
    Neoplasma; 2007; 54(5):437-42. PubMed ID: 17688374
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adjuvant chemotherapy for stage II nonseminomatous germ cell tumors.
    Kondagunta GV; Motzer RJ
    Urol Clin North Am; 2007 May; 34(2):179-85; abstract ix. PubMed ID: 17484923
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Surgical management of low-stage nonseminomatous germ cell testicular cancer.
    Stephenson AJ; Klein EA
    BJU Int; 2009 Nov; 104(9 Pt B):1362-8. PubMed ID: 19840014
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term followup results of 1 cycle of adjuvant bleomycin, etoposide and cisplatin chemotherapy for high risk clinical stage I nonseminomatous germ cell tumors of the testis.
    Westermann DH; Schefer H; Thalmann GN; Karamitopoulou-Diamantis E; Fey MF; Studer UE
    J Urol; 2008 Jan; 179(1):163-6. PubMed ID: 18001800
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Minimizing treatment without compromising cure with primary surveillance for clinical stage I embryonal predominant nonseminomatous testicular cancer: a population based analysis from British Columbia.
    Al-Tourah AJ; Murray N; Coppin C; Kollmannsberger C; Man A; Chi KN
    J Urol; 2005 Dec; 174(6):2209-13, discussion 2213. PubMed ID: 16280765
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Retroperitoneal lymph node dissection in patients with low stage testicular cancer with embryonal carcinoma predominance and/or lymphovascular invasion.
    Stephenson AJ; Bosl GJ; Bajorin DF; Stasi J; Motzer RJ; Sheinfeld J
    J Urol; 2005 Aug; 174(2):557-60; discussion 560. PubMed ID: 16006891
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nonrandomized comparison of primary chemotherapy and retroperitoneal lymph node dissection for clinical stage IIA and IIB nonseminomatous germ cell testicular cancer.
    Stephenson AJ; Bosl GJ; Motzer RJ; Bajorin DF; Stasi JP; Sheinfeld J
    J Clin Oncol; 2007 Dec; 25(35):5597-602. PubMed ID: 18065732
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic factors in nonseminomatous testicular cancer.
    Javadpour N
    Prog Clin Biol Res; 1985; 203():271-86. PubMed ID: 2421330
    [No Abstract]   [Full Text] [Related]  

  • 10. Current management of stage I testicular non-seminomatous germ cell tumours.
    Pectasides D; Pectasides E; Constantinidou A; Aravantinos G
    Crit Rev Oncol Hematol; 2009 May; 70(2):114-23. PubMed ID: 18805019
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Management of patients with clinical stage I nonseminomatous testicular germ cell tumours: active surveillance versus primary chemotherapy versus nerve sparing retroperitoneal lymphadenectomy.
    Heidenreich A; Pfister D
    Arch Esp Urol; 2012 Mar; 65(2):215-26. PubMed ID: 22414450
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evolution of the management of stage I nonseminomatous germ-cell tumors of the testis.
    Sogani PC
    Urol Clin North Am; 1991 Aug; 18(3):561-73. PubMed ID: 1652171
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Retroperitoneal lymph node dissection in patients with high risk testicular cancer.
    Williams SB; McDermott DW; Dock W; Bahnson E; Berry AM; Steele GS; Richie JP
    J Urol; 2009 May; 181(5):2097-101; discussion 2101-2. PubMed ID: 19286227
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical outcome following post-chemotherapy retroperitoneal lymph node dissection in men with intermediate- and poor-risk nonseminomatous germ cell tumour.
    Shayegan B; Carver BS; Stasi J; Motzer RJ; Bosl GJ; Sheinfeld J
    BJU Int; 2007 May; 99(5):993-7. PubMed ID: 17437432
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Retroperitoneal lymph node dissection in the treatment of low-stage nonseminomatous germ cell tumors of the testicle.
    Yoon GH; Stein JP; Skinner DG
    Expert Rev Anticancer Ther; 2005 Feb; 5(1):75-85. PubMed ID: 15757440
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The indication for postchemotherapy lymph node dissection in clinical stage IS nonseminomatous germ cell tumor.
    Dash A; Carver BS; Stasi J; Bajorin DF; Motzer RJ; Bosl GJ; Sheinfeld J
    Cancer; 2008 Feb; 112(4):800-5. PubMed ID: 18172902
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Management of clinical stage I nonseminomatous germ-cell testis tumors.
    Flechon A; Droz JP
    Expert Rev Anticancer Ther; 2003 Feb; 3(1):21-30. PubMed ID: 12597346
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Retroperitoneal lymph node dissection for nonseminomatous germ cell testicular cancer: impact of patient selection factors on outcome.
    Stephenson AJ; Bosl GJ; Motzer RJ; Kattan MW; Stasi J; Bajorin DF; Sheinfeld J
    J Clin Oncol; 2005 Apr; 23(12):2781-8. PubMed ID: 15837993
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Management of advanced germ-cell tumors of the testis.
    Fléchon A; Rivoire M; Droz JP
    Nat Clin Pract Urol; 2008 May; 5(5):262-76. PubMed ID: 18398406
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A case of spermatic cord teratoma in low-stage testicular cancer managed by surveillance.
    Subramanian VS; Gilligan T; Klein EA
    Nat Clin Pract Urol; 2008 Apr; 5(4):220-3. PubMed ID: 18268549
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.